SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

The revenue zoomed 6.52% to Rs. 15706.40 millions for the quarter ended March 2025 as compared to Rs. 14745.50 millions during the corresponding quarter last year.A big decline of -62.68% was reported for the quarter ended March 2025 to Rs. 753.40  millions from Rs. 2018.70 millions of corresponding previous quarter.The Operating Profit of the company witnessed a decrease to 1838.70 millions from 2954.10 millions.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202503 202403 % Var 202503 202403 % Var 202503 202403 % Var
Sales 15706.40 14745.50 6.52 60326.30 58740.60 2.70 60326.30 58740.60 2.70
Other Income 132.10 72.20 82.96 478.90 313.20 52.91 478.90 313.20 52.91
PBIDT 1838.70 2954.10 -37.76 9492.70 10298.40 -7.82 9492.70 10298.40 -7.82
Interest 237.10 101.30 134.06 764.70 544.70 40.39 764.70 544.70 40.39
PBDT 1601.60 2852.80 -43.86 8856.70 9753.70 -9.20 8856.70 9753.70 -9.20
Depreciation 686.00 691.20 -0.75 2770.80 2711.40 2.19 2770.80 2711.40 2.19
PBT 915.60 2161.60 -57.64 6085.90 7042.30 -13.58 6085.90 7042.30 -13.58
TAX 162.20 142.90 13.51 1054.70 377.50 179.39 1054.70 377.50 179.39
Deferred Tax 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
PAT 753.40 2018.70 -62.68 5031.20 6664.80 -24.51 5031.20 6664.80 -24.51
Equity 393.10 393.10 0.00 393.10 393.10 0.00 393.10 393.10 0.00
PBIDTM(%) 11.71 20.03 -41.57 15.74 17.53 -10.25 15.74 17.53 -10.25

Alembic Pharma Share Price

772.85 -12.10 (-1.54%)
20-Apr-2026 12:30 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1672.80
Dr. Reddys Lab 1238.00
Cipla 1238.25
Zydus Lifesciences 942.95
Lupin 2333.90
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×